Background: To obtain a prognostic stratification model for resected gastric cancer patients. Patients and methods: Clinicopathological and molecular data (expression of Cdx2, Apc, β-catenin, E-cadherin, Fhit, p53, and human epidermal growth factor receptor-2 (Her2); HER2 and TOPO2A gene copy number; PIK3CA mutations; microsatellite instability) were correlated to cancer-specific/overall survival (CSS/OS) using a Cox model. Individual patient probability (IPP) was estimated by logistic equation. A continuous score to identify risk-classes was derived according to the model ratios.
introduction
Despite the recent progresses in the development of new therapeutic strategies and in early diagnosis, the prognosis of gastric cancer continues to be poor, with <20% of patients surviving at 5 years [1] . With these perspectives, it becomes of paramount importance to identify factors helping to predict survival and/or response to treatment, to choose better among the available therapeutic tools.
In addition to the proven prognostic indicators (age, sex, gastric wall infiltration, locoregional nodal involvement, Laurens' histology, and margins), a series of molecular markers are currently under investigation as survival predictors [2] [3] [4] .
Among these, the human epidermal growth factor receptor-2 (Her2) abnormalities are the most explored, especially as predictors of response to specific target therapy. A direct correlation between Her2 overexpression or HER2 amplification and poorer survival was recently reported [5, 6] .
The absence or aberrant expression of Fhit represents one of the most frequent molecular alterations occurring in gastric cancer. Nevertheless, its correlation with clinicopathological parameters is under debate; in this regard, many studies support the association of the lack of Fhit expression with disease progression and poorer prognosis [7] [8] [9] .
Widespread somatic alterations in simple repetitive genomic sequences (microsatellites), as a result of defective DNA mismatch repair complex, are detectable in ∼15% of gastric cancers and are associated with a more favorable prognosis, lager size, female gender, advanced age, less lymph node (LN) involvement, intestinal histotype, and antral location [10, 11] .
E-Cadherin and β-catenin are, respectively, a transmembrane and a cytoplasmatic protein involved in epithelial cell-cell interactions, and they are abnormally expressed in almost a half of gastric carcinomas [12, 13] . Many studies have highlighted the influence of mutation/overexpression of p53 on disease progression and survival; in some of them, by the mean of multivariate analysis, p53 status resulted to be an independent prognostic marker [2, 14, 15] .
Adenomatous polyposis coli (APC) gene is the negative regulator of the Wnt/β-catenin pathway. Its inactivation leads to β-catenin accumulation, which constitutively triggers an aberrant transcriptional activation of genes involved in cell proliferation (CMYC, cyclin D1). The functional significance of the APC pathway, extensively documented in colorectal cancer development, is not well defined in gastric carcinogenesis yet [2] .
Other biological markers such as PIK3CA gene mutations, topoisomerase-2A (TOPO2A) gene amplification, and Cdx2 overexpression have been recently associated with gastric carcinogenesis, and sometimes correlated with well-known prognostic factors, although their correlation with survival is still controversial [2, 14, [16] [17] [18] .
The aim of the work presented in this report was to define a risk classification on the basis of the combination of biomolecular and clinicopathological predictors, to provide a practical tool for a better patients' selection from a prognostic perspective.
methods
A step-by-step protocol was followed according to the methodological approach for building a nomogram for cancer prognosis according to Iasonos et al. [19] , with respect to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria for the conduction of a retrospective study in the context of an unselected population [20, 21] .
patients population
Patients who underwent radical surgical resection for gastric cancer at Verona University Hospital (Italy), without receiving any pre-or postoperative chemo-or radiotherapy. Histological classification was according to Laurén, and the updated 2010 7th TNM system for gastric carcinoma was used for pathological staging.
end points
The aim was to generate risk classes [for cancer-specific survival (CSS): primary end point and overall survival (OS): secondary end point] by taking into account the known prognostic clinicopathological factors [age, sex, Lauren's histology, resection margins (R), grading, primary tumor location, primary tumor size, number of resected LNs] and investigational molecular factors. These latter included the immunohistochemical expression of seven proteins: Cdx2, APC, β-catenin, E-cadherin, Fhit, p53, and Her2 [22] ; HER2 and TOPO2A gene copy number by fluorescence in situ hybridization (FISH); PIK3CA mutation (exons 9 and 20); microsatellite instability (MSI).
immunohistochemistry and fluorescence in situ hybridization
Formalin-fixed, paraffin-embedded tissues of 208 cases of gastric cancer and 21 normal gastric mucosae were used to construct tissue microarrays (TMAs), as previously described [23] . Each sample was represented by three cores of 1 mm diameter. TMAs were immunostained using the antibodies listed in Supplementary Table S1, available at Annals of Oncology online. Primary antibodies were omitted in negative controls. Detection was carried out using Dako EnVision Plus-HRP kit (Dako). Slides were scanned with ScanScope® GL System (Aperio Technologies, Vista, CA) and visualized using ImageScope ™ Software (Aperio Technologies). Immunoreactivity evaluation for each antigen is detailed in the Appendix (Methods section). FISH was carried out using HER2 and TOPO2A locus-specific and chromosome 17 centromeric probes (Vysis, Downers Grove, IL) diluted 1 : 100 in tDenHyb1 buffer (Insitus, Albuquerque, MN). The slides were examined using an Olympus BX61 (Bremerhaven, Germany) and the appropriate filters. Annotation of tumors was carried out as previously described [24] [25] [26] .
mutation analysis
Normal and tumor DNA was extracted from manually microdissected paraffin-embedded tissues as described [27] . Mononucleotide microsatellites BAT25 and BAT26 were examined by PCR amplification using fluorescent dye-labeled primers as described [28] . PCR amplification and sequencing of PIK3CA exons 9 and 20 have been carried out as described [16] .
statistics
Descriptive statistics were used to summarize pertinent study information. Follow-up was analyzed and reported according to Shuster [29] . The correlation between variables were analyzed according to chi-square, Student's t, and Mann-Whitney (nonparametric) tests. The hazard ratio (HR) and the 95% confidence intervals (95% CI) were estimated for each variable using the Cox univariate model [30, 31] . A multivariate Cox proportional hazard model was developed using stepwise regression (forward selection, enter/remove limits P = 0.10 and P = 0.15), to identify independent predictors of outcomes. The assessment of interactions between significant investigation variables was taken into account when developing the multivariate model. The martingale residual plots analysis was applied to check the functional form of continuous variables [32] ; in presence of nonlinear distribution of ratios, the receiver operating characteristic (ROC) curve analysis was adopted for dichotomization according to outcome [33, 34] , as well as the analysis by means of maximally selected log-rank statistics [35, 36] . ROC analysis allowed assessing the predictive accuracy of the prognostic model, by the area under the curve (AUC) determination [37] . CSS/OS were calculated by the Kaplan-Meier product limit method from the date of the surgery until death due to cancer or death for any cause [38] . The log-rank test was used to assess differences between subgroups. Significance was defined at the P < 0.05 level. The SPSS® (18.0), R® (2.6.1), SAS® (9.0), and MedCalc® (10.0.1) statistical programs were used for all analyses.
model validation
To address the overfitting of multivariate model and to validate the results, a cross-validation technique that evaluates the replication stability of the final Cox multivariate model in predicting all outcomes was investigated, using a resampling procedure considering those variables independent at the multivariate analysis for at least one outcome [19] . This technique generates a number of simulation datasets (at least 100, each ∼80% of the original size), by randomly selecting patients from the original sample, to establish the consistency of the model across less powered patient samples [19, 39, 40] .
original articles Annals of Oncology individual patient probability A logistic equation including the coefficients of the regression analysis was then constructed to calculate an estimation of individual patient's probability of outcome event (a prespecified time points): probability of event = (Exp∑(X × β) + intercept(α))/(1 + (Exp∑(X × β) + intercept(α))), where X × β is the coefficient β for each single confounding factor [41, 42] . The prognostic accuracy of the found multivariate model was determined by the ROC analysis [37] .
prognostic score assessment
The log-HR obtained from the Cox model were used to derive weighting factors of a prognostic index, aimed at identifying differential risks death by cancer (for CSS) and death (for OS). Coefficients estimates were 'normalized' dividing by the smallest one and rounding the resulting ratios to the nearest integer value [43] . Two methods of modeling were adopted to generate risk classes: (i) for Model A, patient outcome (CSS and OS) as reported according to the determined prognostic score was grouped by selecting cutoffs chosen at approximately equal distance along the range of values; (ii) for Model B, the ROC analysis (confirmed by the maximally selected log-rank statistics) was adopted for the dichotomization of the prognostic score according to outcome (i.e. the best 'splitter' cutoff was Figure S4 , available at Annals of Oncology online), APC expression, and negative Her2 at immunohistochemistry ( Figure 1 ) were significant prognostic predictors. No significant specific pattern of clustering between the biomolecular variables with the exception of HER2 and TOPO2A gene copy number or Her2 immunohistochemistry was seen at the exploratory multiple correspondence analysis (Supplementary Figure S5 , available at Annals of Oncology online).
validation and IPP
At the cross-validation analysis, gender, number of LNs, margins, stage, location, APC, and Fhit were confirmed as independent factors for CSS (replication rate: 76%, 64%, 100%, 100%, 89%, 94%, and 51%, respectively) and gender, number of LNs, margins, stage, localization, age, APC, and Her2, for OS (replication rate: 90%, 68%, 100%, 100%, 84%, 51%, 89%, and 25%, respectively). The determined multivariate model was able to predict the individual patient probability (IPP) with a prognostic accuracy of 90% (SE 0.02) for CSS, and 91% (SE 0.02) for OS, respectively ( Figure 2 ). Figure 1 . Unadjusted survival curves for molecular independent variables at multivariate analyses, for cancer-specific survival (A-C) and overall survival (D-F). p, P value at log-rank analysis.
original articles , and high risk (score >9) of death due to cancer (2-year CSS: 6.3%, 35.3%, and 88.0%, respectively, P < 0.0001) or for any cause (2-year OS: 6.1%, 34.6%, and 86.5%, respectively, P < 0.0001), was determined ( Figure 3 ). The score dichotomization according to outcome carried out with the ROC analysis and the maximally selected log-rank statistics, identified 6 as optimal cutoff point (Supplementary Figure S6 , available at Annals of Oncology online). By this, according to Model B, a highly significant prognostic difference for both outcomes between patients at low (score ≤6), and high risk (score >6) of death due to cancer (2-year CSS: 23.4%, and 85.6%, respectively, P < 0.0001) or for any cause (2-year OS: 21.4%, and 82.0%, respectively, P < 0.0001) was found ( Figure 3) . No difference in the prognostic models' performance according to ROC analysis was found as follows: (i From a power perspective, data may be considered reliable with the obtained overall differences, given that to determine a 2-year survival difference of 20% (significantly less than the 60% determined in this report), 178 patients would have been required ( power 80%, α error 5%).
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discussion
In this report, we have investigated in 208 patients who undergone gastric resection, a series of clinicopathological and molecular markers with already established or putative prognostic role to determine their potential effect as survival predictors on the basis of their different combination. Given the marginal impact of adjuvant chemotherapy for resected patients [45] , the accurate evaluation of prognosis has become of main interest in the attempt to optimize the efficacy of the available therapeutic tools. In this regard, many studies have examined the individual correlation between clinical or pathological parameters and survival, although only a few have attempted to provide a prognostic model [46] [47] [48] . The prognostic model, which is determined in our analysis, combining clinical, pathological, and biomolecular predictors, was capable of dramatically discriminating patients at low and high risk of death and/or death due to cancer, regardless of the method adopted (Figure 3) .
Among the explored predictors, nine parameters, including three molecular markers (immunohistochemical expression status of Her2, Fhit, and APC), achieved independent statistical significance at Cox proportional hazard model (Table 2 ) and were consistent with the cross-validation analysis.
The clinical relevance of the role of Her2 for gastric cancer has been witnessed in the last years, given the introduction of trastuzumab for advanced disease [49] . Nevertheless, its role as a prognostic predictor is currently debatable, given that the available data to date are mostly retrospective, conflicting, and obtained with different methodologies of Her2 determination. Furthermore, according to a recent review carried out by Chua and Merrett, the wide range of Her2 prevalence may be partially confounded by additional issues, such as geographic variations, population size, and distinct scoring systems [50] . In our sample, the Her2 overexpression (occurring in 5.8% of patients) represented an independent predictor of poor prognosis for OS (HR 1.75) (Table 2, Figure 1) ; these data resembles those reporting a trend toward a correlation between Figure 2 . Individual patient probability (IPP) for cancer-specific survival (A) and overall survival (B), on the basis of multivariate analysis; model performance at ROC analysis. AUC, area under the curve; SE, standard error; p, P value at log-rank analysis. original articles
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Her2 high immunohistochemical positivity and poorer outcomes [2, 5, 6] . Conversely, we did not find any significant clinical correlate with HER2 gene amplification as assessed by FISH (occurring in 7.7% of patients), as already reported by Kanta et al. [51] in 38 (6%) of 552 gastric cancer tissues. TOPO2A gene is located closer to HER2 gene and has been reported as coamplified in a small proportion of gastric cancers [52] . In our series, TOPO2A amplification assessed by FISH accounted for 18.3% of the population and was significantly more prevalent in patients overexpressing Her2 by immunohistochemistry (Supplementary Table S2 , available at Annals of Oncology online). Although no impact on survival was determined, the explorative multiple correspondence analyses did show a common pattern of distribution according to outcome between TOPO2A and HER2 (Supplementary Figure S5 , available at Annals of Oncology online). The lack of Fhit expression (which is assumed as the loss of FHIT-gene function), occurring in 65.9% of our sample, was significantly associated with shorter OS and CSS, and resulted to be an independent negative predictor of CSS at the multivariate analysis (Table 2, Figure 1 ). Although existing all biases already described for the Her2 reporting in literature, the loss of Fhit expression in gastric cancer has been previously found ranging from 44% to 78% and evidences on its possible relationship with clinicopathological parameters are conflicting [7] [8] [9] 53] .
With regard to APC, which is suggested to be an early event in a proportion of gastric cancers, the lack of cytoplasm immunoreactivity to the antibody against the carboxyl terminus of the APC protein (occurring in 33.2% of patients in our series) was considered as a valid surrogate for gene inactivation [54] , and it was substantially correlated with shorter CSS and OS at both univariate and multivariate analyses (Table 2, Figure 1 ). These data are supported by a higher replication rate at the cross-validation analysis (94% for CSS and 89% for OS), providing further insights for the investigation of APC as adverse prognostic factor for future research.
Among those factors resulted to substantially discriminate patients at the univariate analysis, p53 nuclear accumulation (which is assumed to reflect gene mutation), occurring in 27.9% of patients, was associated with shorter survival, as reported by previous experiences [2, 15] . Of note, this featured expression was significantly associated with Her2 overexpression (Supplementary Table S2 , available at Annals of Oncology online). Many authors suggested a more favorable prognosis and a less aggressive growth pattern for gastric tumors yielding MSI [10, 11, 55] . In the current analysis, cases harboring MSI (15.9%) had a significantly longer CSS and OS ( Table 2 ). The relative impact on prognosis of these latest factors might have been partially obscured by other 'stronger' predictors, such as stage (replication rate of 100% for both OS and CSS), suggesting the need to investigate those parameters in earlier gastric cancer [10] .
As a major finding, the built multivariate model was capable of significantly determining an IPP of death by cancer and of death by any cause at 2 years with a high accuracy (0.90 and 0.91, respectively) ( Figure 2) . Once assessed the prognostic accuracy of the model, we aimed at discriminating patients according to a continuous score (Table 3) , which was able to differentially stratify patients in three or two classes, on the basis of the adopted method for the score-cutoff identification (Figure 3, Supplementary Figure S6 , available at Annals of Oncology online). Regardless of the class-risk stratification method, both the three-and the two-class models demonstrated a dramatic performance in stratifying patients according to their life expectancy.
The disappointing prognosis of gastric cancer calls for the identification of factors predictive of survival and/or response to treatment. Given the current evidences with regard to (neo)-adjuvant treatment, and the indication to treatment of those patients with residual disease after surgery, the extent that these data may be generalized to clinical practice is actually limited. Besides, to our knowledge, our approach represents one of the earlier attempts to provide a prognostic scoring system, arising from the combination of multiple clinical, pathological, and molecular independent factors, as a powerful tool for helping clinicians in better discriminating the daily patients' prognosis, and at the same time, suggesting additional predictors when investigating treatment optimization strategies for adjuvant setting. Nevertheless, taking into account all biases in the context of a retrospective analysis a prospective validation with a larger sample is currently ongoing. Although definitive conclusions at this early stage should not be drawn, we are not able to exclude future perspectives for these explored biomarkers as potential predictive factors for treatment customization for resected gastric cancer. In this context, we believe that in the forthcoming future, some of the biological factors investigated may have the potential to be incorporated in the decision-making process, along with classical clinical and pathological factors. 
